Clinical Trial Update: BAY63-2521 - Long-term Extension Study in Patients With Chronic Thromboembolic Pulmonary Hypertension [Phase 3]

View source ↗

Summary

Long-term extension Phase 3 trial for BAY63-2521 in chronic thromboembolic pulmonary hypertension has completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboembolic Pulmonary Hypertension

Drugs mentioned

• BAY63-2521

Snippet

Sponsor: Bayer | Conditions: Pulmonary Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2020-10-22